MiMedx

Q2 FY2026 EarningsQ2 FY26 results were mixed with a top-line beat but a bottom-line miss: revenue was $64.4M vs. $63.5M expected, while GAAP EPS was -$0.10 vs. -$0.05 expected. The 34.7% YoY revenue decline was primarily driven by a 61.1% drop in the Wound segment due to Medicare reimbursement changes, partially offset by 15.1% growth in the Surgical segment. Management announced a definitive agreement to acquire Sanara MedTech for ~$350M, signaling a major strategic shift toward inorganic growth despite ongoing reimbursement headwinds.